@sillz's Ozempic bone damage claims, fact-checked

What did @sillz actually say?

The creator opened with a bold frame: Ozempic has "stopped being a magic pill and is now shredding bones." The core claim is that GLP-1 drugs increase osteoporosis risk by about 30%, based on unspecified "new studies." The video then pivots to a secondary argument: the real culprit might not be the drug itself, but the nutritionally poor diets users were already eating before starting it.

That second argument is more interesting than the first, and it deserves a fair reading. The creator is suggesting that people who use GLP-1 medications often come in with pre-existing micronutrient deficiencies, and that aggressive calorie reduction on a low-quality diet could deplete calcium, magnesium, and vitamin D further. It is a mechanistic hypothesis, not a confirmed finding. But it is not absurd.

Does the science back this up?

The 30% figure is not fabricated, but the framing strips away almost all the context that makes it meaningful. A 2024 observational study published in JAMA Network Open (Li et al., 2024) found associations between GLP-1 receptor agonist use and increased fracture risk in certain populations, but the effect sizes varied widely and were heavily confounded by pre-existing conditions like type 2 diabetes, which independently raises fracture risk.

It is worth noting that diabetes itself is an independent risk factor for bone fragility. Patients with type 2 diabetes often have higher bone mineral density but worse bone quality, a paradox that complicates any attempt to isolate what a GLP-1 drug is doing on its own. Additionally, the rapid fat and lean mass loss associated with these medications, particularly muscle loss, is a genuine concern for bone health. A 2023 review in Obesity Reviews (Prado et al., 2023) documented significant lean mass loss alongside fat loss in GLP-1 users, which has downstream implications for bone loading and density over time.

What did they get wrong (or right)?

The creator got the general concern directionally right: bone health is a legitimate and underreported consideration with GLP-1 medications. That is a fair point to raise. The specific 30% risk claim, though, is stated as though it is a settled, drug-direct finding. It is not. Observational data in metabolically ill populations cannot cleanly attribute fracture or osteoporosis risk to the medication alone.

The dietary argument has some biological plausibility. Calcium and vitamin D insufficiency are already widespread in the general population, and a dramatic calorie reduction on an already poor diet could accelerate deficits. However, the creator's framing that users are presumed to eat "nutrient-devoid food" and to have "failed" natural weight loss is speculative and stigmatizing. GLP-1 medications are prescribed across a wide range of patients with different dietary histories. The claim that these people "resort" to Ozempic implies failure in a way that does not reflect the clinical reality of obesity as a metabolic condition.

What should you actually know?

If you are on a GLP-1 medication, bone health is worth a real conversation with your prescriber. The concern is not invented. The mechanisms under discussion include reduced calorie intake, possible lean mass loss, and direct effects of GLP-1 receptors on bone remodeling, though the last one is still being actively studied.

A few things are well-supported by evidence:

• Protein intake during GLP-1-assisted weight loss is associated with better preservation of lean mass, which supports bone loading (Prado et al., 2023, Obesity Reviews).
• Resistance training during weight loss reduces bone density decline (Cava et al., 2017, Nutrients).
• Calcium and vitamin D monitoring is standard of care in patients losing weight rapidly, regardless of how that weight loss is achieved.

What is not well-supported is the framing that Ozempic is "shredding bones" as a direct pharmacological effect. The signal in current data is real but observational, confounded, and not settled science. Anyone citing a clean 30% number without acknowledging those caveats is oversimplifying.